Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A new biotech hotspot could be on the horizon in Oregon thanks to a $500 million gift to the University of Oregon from Nike co-founder Phil Knight, an alumnus of the university.
Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.
Josh Smiley’s termination from Eli Lilly for inappropriate communications with employees will cost more than a blow to his reputation.
As part of the Takeda deal, Ensoma will do preclinical research for therapies in up to five rare disease indications, and both companies will work on Investigational New Drug-enabling studies.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.
AbbVie committed up to another $300 in potential milestone payments.
There have been a few life sciences companies that have been attracting attention this week with strong Series A rounds.
The choice for the new FDA commissioner will tell the public about the Biden administration’s battle plan with regards to handling the global pandemic.
BigHat is a Bay-area startup that’s reimagining antibody development with the help of AI and ML (machine learning) technologies through data-driven discovery.